Article: Drug-eluting stents/One of the authors responds

In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.1 They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the study authors recommended against the widespread use of drug-eluting stents. However, we believe that previously published cost analyses of drug-eluting stents, including those mentioned by Ligthart and associates, may have failed to consider the potential costs of lifetime therapy with clopidogrel.

Recent evidence suggests that cessation of clopidogrel therapy in patients with drug-eluting stents can lead ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!